同仁堂（600085）医养向港交所主板递交上市申请，由中金公司（601995）担任保荐人。 按2024年总门诊人次及住院人次计，公司是中国非公立中医院医疗服务行业中最大的中医院集团，市场 份额为1.7%。 同仁堂医养是同仁堂集团旗下专注于中国中医医疗服务的战略性附属公司，业务包括向个人客户提供中 医医疗服务、向机构客户提供标准化管理服务，以及销售健康产品及其他产品。公司已建立分级中医医 疗服务网络，包括12家自有营利性线下医疗机构(7家医院、3家门诊部、2家诊所)和一家互联网医院， 以及12家非营利性线下管理医疗机构。 中国中医医疗服务市场具有巨大增长潜力，预计其市场规模将从2024年的10016亿元人民币增至2029年 的16205亿元人民币，复合年增长率为9.9%。 按2024年中医医疗服务总收入计，同仁堂医养在非公立中医院医疗服务行业中排名第二，市场份额为 0.2%。 ...

据港交所1月26日披露，北京同仁堂医养投资股份有限公司（简称：同仁堂医养）向港交所主板递交上 市申请书，中金公司为其保荐人。 招股书显示，同仁堂医养是同仁堂旗下一家战略性聚焦于中国中医医疗服务的附属公司，为个人客户提 供全面中医医疗服务，为机构客户提供标准化管理服务，并提供各种健康产品及其他产品。公司已建立 分级中医医疗服务网络，包括12家自有线下医疗机构及一家互联网医院，以及12家线下管理医疗机构。 按2024年总门诊人次及住院人次计，公司是中国非公立中医院医疗服务行业中最大的中医院集团，市场 份额为1.7%。 港股频道更多独家策划、专家专栏，免费查阅>>责任编辑：栎树 ...

智通财经APP获悉，据港交所1月26日披露，北京同仁堂医养投资股份有限公司(简称：同仁堂医养)向港 交所主板递交上市申请书，中金公司为其保荐人。招股书显示，同仁堂医养是同仁堂旗下一家战略性聚 焦于中国中医医疗服务的附属公司，为个人客户提供全面中医医疗服务，为机构客户提供标准化管理服 务，并提供各种健康产品及其他产品。公司已建立分级中医医疗服务网络，包括12家自有线下医疗机构 及一家互联网医院，以及12家线下管理医疗机构。按2024年总门诊人次及住院人次计，公司是中国非公 立中医院医疗服务行业中最大的中医院集团，市场份额为1.7%。 | :[编纂]股H股(視乎[編纂]行使與否而定) | 編纂]項下的[編纂]數目 | | --- | --- | | [編纂]數目 [编纂]股H股(可予[編纂]) | . . | | [編纂]數目 : [编纂]股H股(可予[編纂]及 | | | 視乎[編纂]行使與否而定) | | | 最高[編纂] : 每股H股[編纂]港元,另加1.0%經 | | | 紀佣金、0.0027%證監會交易徵 | | | 費、0.00015% 會財局交易徵費及 | | | 0.00565%聯交所交易費(須於 ...

Group 1 - The core point of the article is that Tongrentang Medical Investment Co., Ltd. has submitted its third listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. If successful, it will become the fourth listed platform under the Tongrentang Group [1] Group 2 - Tongrentang Medical is a traditional Chinese medicine healthcare group providing comprehensive medical services to individual clients and standardized management services to institutional clients, along with various pharmaceutical and other products [5] - As of the latest feasible date, Tongrentang Medical has established a tiered medical service network, including 12 self-owned offline medical institutions and one internet hospital, as well as 10 offline managed medical institutions [5] - By 2024, Tongrentang Medical is the largest non-public traditional Chinese medicine hospital group in China, holding a market share of 1.7% in terms of total outpatient and inpatient visits [5] - In terms of total medical service revenue for 2024, Tongrentang Medical accounts for 46.5% of the total market size of the traditional Chinese medicine healthcare service industry in China [5] - The company's revenue primarily comes from medical services, management services, and sales of health products and other products, with medical services generating approximately 995 million yuan, management services about 9.6 million yuan, and health product sales around 138 million yuan for the fiscal year 2023 [5] - The company's revenue for the fiscal years 2022, 2023, and 2024 was approximately 911 million yuan, 1.153 billion yuan, and 1.175 billion yuan respectively, with net profits of -9.233 million yuan, 42.634 million yuan, and 46.197 million yuan during the same periods [5]

Group 1 - The core viewpoint of the news is that Beijing Tongrentang Medical Investment Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The company is a traditional Chinese medicine (TCM) healthcare group that provides comprehensive TCM medical services to individual clients and standardized management services to institutional clients [4] - As of June 24, 2025, the company has established a tiered medical service network, including 12 self-owned offline medical institutions and one internet hospital, along with 10 offline managed medical institutions [4] Group 2 - The company is the largest TCM hospital group in China's non-public hospital sector, with a market share of 1.7% based on total outpatient and inpatient visits in 2024 [4] - The company ranks second in the non-public TCM hospital sector with a market share of 0.2% based on total medical service revenue in 2024, capturing 46.5% of the total market size of China's TCM medical services [4] - Revenue sources for the company include medical services, management services, and sales of health products, with medical services generating approximately 995 million RMB, management services about 9.6 million RMB, and health product sales around 138 million RMB for the fiscal year 2023 [4] Group 3 - The company's revenue for the fiscal years 2022, 2023, and 2024 was approximately 911 million RMB, 1.15 billion RMB, and 1.18 billion RMB, respectively, with net profits of -9.23 million RMB, 42.63 million RMB, and 46.2 million RMB during the same periods [6][7] - The gross profit for the same years was approximately 142.77 million RMB, 217.48 million RMB, and 222.5 million RMB, indicating a steady increase in profitability [7]